source
- Argenx to acquire macrocycle biotech Unnatural Products in up to $1.15 billion dealArgenx announced Monday it will acquire Unnatural Products, a biotech focused on macrocycle therapeutics that began as a garage startup. The transaction is structured as an up-to-$1.15 billion dea…
- Zura Bio’s Phase 2 trial of tibulizumab fails, shares plungeZura Bio announced that its experimental drug tibulizumab did not meet efficacy endpoints in a Phase 2 study of a painful skin disorder. The company said that both dose levels performed no better t…